Search ADMA
ADMA BIOLOGICS, INC.
Nasdaq · CIK 1368514
Last close9.72
Daily change-0.21 (-2.11%)
10 Years gain+34.44%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ADMA · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
81.3Momentum
96.6Acceleration
58.0Confidence
83.0Annual Revenue15
Quarterly Revenue53
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth23.8 / 25
Quality18.8 / 25
Capital Efficiency20.0 / 20
Balance Sheet10.5 / 15
Shareholder Economics4.2 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 11.3004 percentage points.
Operating leverageOperating margin improved by 9.3217 percentage points.
Share count reductionDiluted share count declined 5.8605%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
ROIC declining · MEDIUMROIC declined by 16.1462 percentage points.
Possible growth trap · HIGHRevenue growth is high, but quality indicators are deteriorating.
Key Metrics
Revenue Growth TTM16.85%OK
Revenue CAGR 3Y49.05%OK
Gross Margin62.59%OK
Operating Margin41.31%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC38.31%OK
Incremental Operating Margin 3Y65.69%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-5.86%OK
SBC / Revenue4.54%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $510.17M | $292.77M | $191.44M | $50.40M | $27.82M | 57.39% | 37.53% | 5.45% | 39.48% | 244.9M |
| 2025 FY Dec 31, 2024 | $426.45M | $219.55M | $138.98M | $118.67M | $110.45M | 51.48% | 32.59% | 25.9% | 44.94% | 243.34M |
| 2025 FY Dec 31, 2023 | $258.22M | $88.94M | $21.63M | $8.80M | $4.03M | 34.44% | 8.38% | 1.56% | 22.89% | 223.98M |
| 2024 FY Dec 31, 2022 | $154.08M | $35.27M | -$39.37M | -$59.51M | -$73.42M | 22.89% | -25.55% | -47.65% | -39.99% | 197.87M |
| 2023 FY Dec 31, 2021 | $80.94M | $1.17M | -$58.37M | -$112.37M | -$125.88M | 1.45% | -72.12% | -155.52% | -75.34% | 139.58M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $495.10M | sum latest 4 fiscal quarters Revenue | OK | 0001140361-26-031445, 0001140361-25-040578 |
| Revenue Growth TTM | 16.85% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001140361-26-031445, 0001140361-25-040578 |
| Revenue CAGR 3Y | 49.05% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001140361-26-006815 |
| Revenue CAGR 5Y | 64.6% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001140361-26-006815 |
| Gross Profit CAGR 3Y | 102.48% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001140361-26-006815 |
| Operating Income Growth | 50.9% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001140361-26-031445, 0001140361-25-040578 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 62.59% | Gross Profit / Revenue | OK | 0001140361-26-031445, 0001140361-25-040578 |
| Operating Margin | 41.31% | Operating Income / Revenue | OK | 0001140361-26-031445, 0001140361-25-040578 |
| ROIC | 38.31% | NOPAT / Average Invested Capital | OK | 0001140361-26-031445, 0001140361-25-040578 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001140361-26-031445 |
| Current Ratio | 6.97x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.69x | (Cash + Short-term Investments) / Total Debt | OK | 0001140361-26-031445 |
| SBC / Revenue | 4.54% | SBC / Revenue | OK | 0001140361-26-031445, 0001140361-25-040578 |